We are live on !
Find out more
Profund Advisors Portfolio holdings
AUM
$3.48B
Turnover
14.37%
1-Year Est. Return
66.96%
ProFund Advisors manages the ProFunds mutual funds, which include index funds across sectors, bonds, currencies and crypto, as well as leveraged and inverse funds. The ProFunds brand dates from 1997, and its affiliate ProShares began offering leveraged and inverse ETFs in 2006. The Bitcoin ProFund tracks bitcoin futures rather than holding bitcoin itself.
This Fund
S&P 500
This Quarter Est. Return
+3.6%
1 Year Est. Return
+66.96%
3 Year Est. Return
+258.11%
5 Year Est. Return
+342.15%
10 Year Est. Return
+1,333.1%
AUM
$3.48B
AUM Growth
-$153M
(-4.2%)
Cap. Flow
-$155M
Cap. Flow % of AUM
Cap. Flow %
-4.44%
Top 10 Holdings %
Top 10 Hldgs %
41.36%
Holding
1,225
New
50
Increased
319
Reduced
729
Closed
126
Avg Time Held
6.2
years
Top 10 Avg Time Held
4.5
years
Top 20 Avg Time Held
5.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SpaceX
SPCX
|
+$37.8M |
| 2 |
Alumis Inc
ALMS
|
+$2.98M |
| 3 |
Collegium Pharmaceutical
COLL
|
+$1.65M |
| 4 |
Reddit
RDDT
|
+$1.57M |
| 5 |
Septerna Inc
SEPN
|
+$1.45M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$46.8M |
| 2 |
Broadcom
AVGO
|
+$15.2M |
| 3 |
Micron Technology
MU
|
+$13.3M |
| 4 |
Apple
AAPL
|
+$12.8M |
| 5 |
Advanced Micro Devices
AMD
|
+$10.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 54.2% |
| 2 | Healthcare | 10.88% |
| 3 | Communication Services | 8.15% |
| 4 | Consumer Discretionary | 7.38% |
| 5 | Industrials | 4.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
201
Boeing
BA
$139B
| $2.01M | 0.06% |
10,809
-957
| -8% | -$205K |
2013 Q2
53 quarters
|
|
202
Madrigal Pharmaceuticals
MDGL
$10B
| $2M | 0.06% |
3,960
+1,110
| +39% | +$587K |
2022 Q4
15 quarters
|
|
203
Ciena
CIEN
$40.3B
| $1.99M | 0.06% |
5,645
-602
| -10% | -$232K |
2013 Q2
53 quarters
|
|
204
Petrobras
PBR
$136B
| $1.98M | 0.06% |
94,938
-4,858
| -5% | -$92.3K |
2013 Q2
53 quarters
|
|
205
Praxis Precision Medicines
PRAX
$7.98B
| $1.97M | 0.06% |
6,764
+667
| +11% | +$221K |
2024 Q2
9 quarters
|
|
206
Ligand Pharmaceuticals
LGND
$6.12B
| $1.95M | 0.06% |
6,253
+4,104
| +191% | +$1.21M |
2024 Q2
9 quarters
|
|
207
Amneal Pharmaceuticals
AMRX
$7.12B
| $1.95M | 0.06% |
96,883
+71,343
| +279% | +$1.29M |
2023 Q4
11 quarters
|
|
208
TJX Companies
TJX
$155B
| $1.94M | 0.06% |
14,639
+820
| +6% | +$118K |
2013 Q2
53 quarters
|
|
209
Xeris Biopharma Holdings
XERS
$1.85B
| $1.94M | 0.06% |
202,547
+169,836
| +519% | +$1.43M |
2024 Q1
10 quarters
|
|
210
Cogent Biosciences
COGT
$5.16B
| $1.93M | 0.06% |
60,425
+14,199
| +31% | +$525K |
2023 Q1
14 quarters
|
|
211
Veradermics Inc
MANE
$5.84B
| $1.92M | 0.06% |
15,843
+12,673
| +400% | +$1.39M |
2026 Q2
1 quarter
|
|
212
Insmed
INSM
$24B
| $1.92M | 0.06% |
16,806
+2,204
| +15% | +$260K |
2023 Q1
14 quarters
|
|
213
Arrowhead Research
ARWR
$8.41B
| $1.92M | 0.06% |
29,282
+7,092
| +32% | +$574K |
2020 Q2
25 quarters
|
|
214
Verizon
VZ
$187B
| $1.91M | 0.05% |
41,705
-8,675
| -17% | -$408K |
2013 Q2
53 quarters
|
|
215
Kymera Therapeutics
KYMR
$10.9B
| $1.89M | 0.05% |
16,909
-1,546
| -8% | -$177K |
2023 Q1
14 quarters
|
|
216
AT&T
T
$144B
| $1.87M | 0.05% |
76,744
-18,794
| -20% | -$453K |
2013 Q2
53 quarters
|
|
217
BridgeBio Pharma
BBIO
$14.6B
| $1.87M | 0.05% |
28,452
+8,523
| +43% | +$664K |
2023 Q1
14 quarters
|
|
218
Viatris
VTRS
$21.4B
| $1.87M | 0.05% |
105,537
+76,500
| +263% | +$1.29M |
2013 Q2
53 quarters
|
|
219
Erasca
ERAS
$4.91B
| $1.86M | 0.05% |
127,107
+22,532
| +22% | +$394K |
2025 Q4
3 quarters
|
|
220
Dianthus Therapeutics
DNTH
$4.61B
| $1.86M | 0.05% |
21,154
+2,607
| +14% | +$271K |
2025 Q4
3 quarters
|
|
221
Kodiak Sciences
KOD
$6.14B
| $1.86M | 0.05% |
19,627
-1,408
| -7% | -$58.1K |
2025 Q4
3 quarters
|
|
222
Abbott
ABT
$191B
| $1.86M | 0.05% |
18,789
-613
| -3% | -$64K |
2013 Q2
53 quarters
|
|
223
ON Semiconductor
ON
$27.3B
| $1.84M | 0.05% |
23,924
-3,272
| -12% | -$263K |
2014 Q1
50 quarters
|
|
224
Coeur Mining
CDE
$13.7B
| $1.83M | 0.05% |
104,055
-1,838
| -2% | -$33.4K |
2013 Q3
52 quarters
|
|
225
Freeport-McMoran
FCX
$90.4B
| $1.81M | 0.05% |
25,859
-14,236
| -36% | -$969K |
2013 Q2
53 quarters
|
|
Similar funds
TC
Profund Advisors's Q3 2026 Portfolio in Review
As of Q3 2026, Profund Advisors held 1,225 positions worth $3.48B, down 4.2% from $3.64B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Profund Advisors withdrew a net $155M in Q3 2026, closing 126 positions and reducing 729 holdings. Its most notable exit was Electronic Arts, an estimated $5.2M position sold in full.
By sector, the portfolio is most concentrated in Technology at 54% of assets, down from 56% a quarter earlier, followed by Healthcare and Communication Services.
Against the trend, Profund Advisors opened a new position in SpaceX worth $41.3M.
- Profund Advisors's largest Q3 2026 buy was SpaceX: 273,453 shares worth $41.3M.
- Profund Advisors added most to Alumis Inc in Q3 2026, an estimated $2.98M increase.
- Profund Advisors's biggest Q3 2026 reduction was NVIDIA, cutting an estimated $46.8M.
- Profund Advisors fully exited Electronic Arts in Q3 2026, selling an estimated $5.2M.
- Profund Advisors's ten largest holdings make up 41% of its $3.48B portfolio in Q3 2026.
- Profund Advisors opened 50 new positions and closed 126 in Q3 2026.
- Profund Advisors's portfolio value fell 4.2% quarter-over-quarter to $3.48B.
Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.